Inzoboon 1000mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin is a first-in-class tetrahydrotriazine compound that exerts its therapeutic effects by targeting mitochondrial bioenergetics, thereby improving insulin sensitivity and enhancing glucose-dependent insulin secretion. This dual mechanism of action addresses both insulin resistance and beta-cell dysfunction, key pathophysiological features of type 2 diabetes. Inzoboon is administered once daily and can be used as monotherapy or in combination with other antidiabetic agents to achieve optimal glycemic control. Clinical studies have demonstrated that Imeglimin effectively reduces HbA1c levels with a favorable safety profile, exhibiting minimal risk of hypoglycemia and weight gain. It is well tolerated, with the most common adverse effects being mild gastrointestinal symptoms such as nausea and diarrhea, which typically resolve with continued use. Inzoboon should be prescribed with caution in patients with renal impairment, and dosage adjustments may be necessary. Regular monitoring of blood glucose and renal function is recommended during therapy. Overall, Inzoboon 1000mg Tablet represents an innovative and effective option for improving glycemic control in adults with type 2 diabetes mellitus.